Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 60 mg Commercial Tablet (Test) to the 60 mg Clinical Tablet (Reference)

Trial Profile

Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 60 mg Commercial Tablet (Test) to the 60 mg Clinical Tablet (Reference)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2015

At a glance

  • Drugs Idalopirdine (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 06 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 02 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top